Eli Lilly, Novo Nordisk boost weight loss drug supply
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should …
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should …
Shares of Danish pharmaceutical giant Novo Nordisk slid 4% on Friday, extending a 2.7% loss on Thursday as analysts pored over the details of the firm’s first-quarter results and monitored a potential rival …
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Thursday said it will stop developing its …
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly …
Microsoft delivered picture-perfect earnings after the bell Thursday, calming the market’s brief fears about runaway spending on AI infrastructure without the cloud revenues to show for it. Revenue increased about …
The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company Novo Nordisk. Joel Saget | AFP | Getty Images The U.S. Senate has launched an investigation into the high price …
Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after …
These are the 2024 top companies in India, according to LinkedIn. Deepak Sethi | E+ | Getty Images LinkedIn has released its eighth annual list of top companies to work …
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Eli Lilly on Wednesday said its …
Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. But that might not be enough to …